These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 36380619)

  • 1. Effect of Bilastine on Chronic Urticaria: A Systematic Review and Meta-Analysis.
    Xue X; Wang Q; Yang X; Tu H; Deng Z; Kong D; Liu W; Fan Z; Li N
    Int Arch Allergy Immunol; 2023; 184(2):176-185. PubMed ID: 36380619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Impact of Bilastine on Symptoms of Allergic Rhinitis and Chronic Urticaria: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Abdelshafy AM; Abdallah SY; Hassan AF; Mohamed HA; Kamal NM; Ali ST; Abdelhaleem IA
    Am J Rhinol Allergy; 2022 Sep; 36(5):684-694. PubMed ID: 35593100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of bilastine in Japanese patients with chronic spontaneous urticaria: A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II/III study.
    Hide M; Yagami A; Togawa M; Saito A; Furue M
    Allergol Int; 2017 Apr; 66(2):317-325. PubMed ID: 27599913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of bilastine in reducing pruritus in patients with chronic spontaneous urticaria and other skin diseases: an exploratory study.
    Serra E; Campo C; Novák Z; Majorek-Olechowska B; Pulka G; García-Bea A; Labeaga L
    J Dermatolog Treat; 2020 May; 31(3):270-278. PubMed ID: 30835579
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study.
    Zuberbier T; Oanta A; Bogacka E; Medina I; Wesel F; Uhl P; Antépara I; Jáuregui I; Valiente R;
    Allergy; 2010 Apr; 65(4):516-28. PubMed ID: 19860762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness, safety, and tolerability of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic spontaneous urticaria: A double-blind, parallel group, randomized controlled trial.
    Podder I; Das A; Ghosh S; Biswas D; Sengupta S; Chowdhury SN
    Dermatol Ther; 2020 Nov; 33(6):e13946. PubMed ID: 32618048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. One-year safety and efficacy study of bilastine treatment in Japanese patients with chronic spontaneous urticaria or pruritus associated with skin diseases.
    Yagami A; Furue M; Togawa M; Saito A; Hide M
    J Dermatol; 2017 Apr; 44(4):375-385. PubMed ID: 27862227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Efficacy and Acceptability of Licensed Dose Second-Generation Antihistamines in Chronic Spontaneous Urticaria: A Network Meta-Analysis.
    Phinyo P; Koompawichit P; Nochaiwong S; Tovanabutra N; Chiewchanvit S; Chuamanochan M
    J Allergy Clin Immunol Pract; 2021 Feb; 9(2):956-970.e57. PubMed ID: 32916325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bilastine: in allergic rhinitis and urticaria.
    Carter NJ
    Drugs; 2012 Jun; 72(9):1257-69. PubMed ID: 22686617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of switching to bilastine, a histamine H1 receptor antagonist, in patients with chronic spontaneous urticaria (H1-SWITCH): study protocol for a randomized controlled trial.
    Fukunaga A; Oda Y; Washio K; Omori T; Kakei Y; Hide M; Nishigori C
    Trials; 2020 Jan; 21(1):23. PubMed ID: 31906999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of Xiaofeng powder in the treatment of chronic urticaria: A systematic review and meta-analysis.
    Bi C; Jia Y; Wei F
    Medicine (Baltimore); 2024 Mar; 103(12):e37305. PubMed ID: 38518009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bilastine: a lifetime companion for the treatment of allergies.
    Church MK; Tiongco-Recto M; Ridolo E; Novák Z
    Curr Med Res Opin; 2020 Mar; 36(3):445-454. PubMed ID: 31612732
    [No Abstract]   [Full Text] [Related]  

  • 13. Real-Life Experience of Efficacy and Safety of Bilastine in the Refractory Cases of Chronic Spontaneous Urticaria and its Effect on the Quality of Life of Patients.
    De A; Godse K; Dhoot D; Sarda A
    Indian J Dermatol; 2021; 66(2):159-164. PubMed ID: 34188271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: A systematic review for the EAACI Biologicals Guidelines.
    Agache I; Rocha C; Pereira A; Song Y; Alonso-Coello P; Solà I; Beltran J; Posso M; Akdis CA; Akdis M; Brockow K; Chivato T; Del Giacco S; Eiwegger T; Eyerich K; Giménez-Arnau A; Gutermuth J; Guttman-Yassky E; Maurer M; Ogg G; Ong P; O'Mahony L; Schwarze J; Werfel T; Canelo-Aybar C; Palomares O; Jutel M
    Allergy; 2021 Jan; 76(1):59-70. PubMed ID: 32767573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Bilastine in the Treatment of Allergic Rhinitis: A Systematic Review and Meta-analysis.
    Singh Randhawa A; Mohd Noor N; Md Daud MK; Abdullah B
    Front Pharmacol; 2021; 12():731201. PubMed ID: 35082662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and safety of bilastine in children aged 6 to 11 years with allergic rhinoconjunctivitis or chronic urticaria.
    Rodríguez M; Vozmediano V; García-Bea A; Novák Z; Yáñez A; Campo C; Labeaga L
    Eur J Pediatr; 2020 May; 179(5):801-805. PubMed ID: 31919579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Omalizumab for Chronic Spontaneous Urticaria: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Jia HX; He YL
    Am J Ther; 2020; 27(5):e455-e467. PubMed ID: 32427616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Open-label safety assessment of bilastine in elderly patients with allergic rhinoconjunctivitis and/or urticaria.
    Sologuren A; Viñas R; Cordón E; Riesgo SE; Del Mar Forés M; Senán MR; Fernández S; Labeaga L; Ruiz-Miján M
    Allergy Asthma Proc; 2018 Jul; 39(4):299-304. PubMed ID: 29559031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients.
    Bachert C; Kuna P; Sanquer F; Ivan P; Dimitrov V; Gorina MM; van de Heyning P; Loureiro A;
    Allergy; 2009 Jan; 64(1):158-65. PubMed ID: 19132976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.